Wednesday, February 09, 2022 1:32:08 PM
..Warrants granted in the year ended December 31, 2020 were valued using the Black Scholes Model..expected volatility ranging of 411.72%
..Series BB Preferred Stock.. calculated at a price of $1.20..
..Global Stem Cells Group’s operations cover every aspect of the regenerative medicine industry.
..$11,600,000.. have a three (3) year maturity date
..Revenue from viable cell therapy and immune support related products along with physician training was $153,583 from August 19, 2021 to September 30, 2021. The key reason for the increase in revenue was a result of the acquisition of Global Stem Cells Group.
..Other expense decreased by $6,460,049 for the three months ended September 30, 2021
https://www.sec.gov/ix?doc=/Archives/edgar/data/1760026/000121390021066881/f10q0921_mesonumis.htm
Little over a month, $153K from cell-Immune therapy and training during all while Covid disruption.
Recent MSSV News
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
